|
Mar 28
|
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know
|
|
Mar 28
|
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks
|
|
Mar 27
|
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 12
|
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely
|
|
Feb 6
|
Acrivon Therapeutics announces FDA granted BDD for ACR-368
|
|
Feb 6
|
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay
|
|
Feb 5
|
Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status
|
|
Feb 5
|
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
|
|
Jun 21
|
Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?
|
|
Jun 5
|
Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?
|
|
Feb 8
|
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
|
|
Feb 6
|
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
|
Nov 28
|
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
|
|
Nov 9
|
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
|
|
Aug 17
|
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 20
|
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
|
|
Apr 25
|
Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
|